Simplified Chinese

English

Home page

The Shenzhen Center for Disease Control and Prevention has signed a strategic cooperation agreement with Kintgen Biotech.

Release date:

2022-05-20

Author:

Source:

Abstract

On the morning of May 20, the Shenzhen Center for Disease Control and Prevention and Shenzhen Kangtai Biological Products Co., Ltd. signed a strategic cooperation agreement, under which the two parties will collaborate on the research and development of vaccines targeting emerging COVID‑19 variants. Zou Xuan, Party Secretary and Director of the Shenzhen CDC, and Du Weimin, Chairman of Kangtai Biological, jointly attended the signing ceremony. The Shenzhen CDC boasts a large pool of highly skilled professionals and state-of-the-art research platforms, playing a pivotal role in disease prevention and control as well as emergency response to public health crises within the Guangdong–Hong Kong–Macao Greater Bay Area. Kangtai Biological, guided by the mission “to create better vaccines and benefit human health,” integrates research, manufacturing, and sales…

5 month 20 On the morning of [date], the Shenzhen Center for Disease Control and Prevention and Shenzhen Kangtai Biological Products Co., Ltd. signed a strategic cooperation agreement, under which the two parties will collaborate on the research and development of vaccines targeting emerging SARS-CoV‑2 variants.

Zou Xuan, Party Secretary and Director of the Shenzhen Center for Disease Control and Prevention, and Du Weimin, Chairman of Kangtai Biological, jointly attended the signing ceremony.

The Shenzhen Center for Disease Control and Prevention boasts a large pool of highly qualified technical professionals and state-of-the-art research platforms, playing a pivotal role in disease prevention and control as well as emergency response to public health crises within the Guangdong–Hong Kong–Macao Greater Bay Area.

Kangtai Biological, with the mission of “creating better vaccines to benefit human health,” is a leading vaccine enterprise integrating research and development, manufacturing, and sales, and possesses… 8 marketed vaccine products, 2 A product for emergency use. Following the outbreak of the COVID‑19 pandemic, Kintgen Biotech stepped up to the challenge, promptly mobilizing its core strengths to advance vaccine development. It became the first company worldwide to achieve production on two distinct technological platforms—inactivated vaccines and adenovirus‑vector COVID‑19 vaccines—and to obtain emergency use authorization.

Through this collaboration, both parties will accelerate the development of vaccines targeting emerging SARS‑CoV‑2 variants, ensuring that scientific advances promptly support the national fight against the pandemic and contribute to epidemic prevention and control efforts across the Guangdong–Hong Kong–Macao Greater Bay Area and throughout China. At the same time, they will establish a long-term strategic partnership to jointly build a cutting-edge platform for vaccine research and development and a hub of technological excellence in vaccine manufacturing, achieving efficient resource integration and complementary strengths, thereby making greater contributions to the restructuring of the vaccine industry chain and to disease prevention.

Keywords:

Leaders from the Biologics Division of the Pharmaceutical and Biological Products Review Department of the China National Intellectual Property Administration paid a visit to our company to conduct research and provide guidance.

Everything for Employee Health: The Company Hosts a Occupational Health Awareness and Consultation Day Event.

Recommended Reading

Batch Release Status of the Company’s Products in 2026

The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.

Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.

Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09

Online Customer Service

Telephone

400 189 9806

Contact Information

Customer Service Hotline

4001899806

Phone number

010-59613600

Official Website

http://www.biominhai.com

Company Address

No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing

WeChat Official Account

Business license

Website Development: China Enterprise Dynamics

Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.